MAP2K7 and craniopharyngioma: In literature, there have been several reports of remarkable responses to BRAF and/or MEK inhibitors (vemurafenib, dabrafenib, and combination therapy) in craniopharyngiomas in various stages, since the discovery that PCPs often harbor BRAF gene mutation (Table 2).